<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">27886643</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>03</Month>
            <Day>10</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1532-3080</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>31</Volume>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Breast (Edinburgh, Scotland)</Title>
                <ISOAbbreviation>Breast</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cardiac safety of adjuvant non-pegylated liposomal doxorubicin combined with cyclophosphamide and followed by paclitaxel in older breast cancer patients.</ArticleTitle>
            <Pagination>
                <MedlinePgn>186-191</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0960-9776(16)30236-3</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.breast.2016.11.006</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To investigate the cardiac safety of adjuvant Non-Pegylated Liposomal Doxorubicin (NPL-DOX) combined to Cyclophosphamide (CTX) and followed by weekly Paclitaxel, in older patients (≥65 years) with diagnosis of high risk breast cancer. The main end point of this prospective study was the detection of early episodes of symptomatic congestive heart failure (CHF).</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">The cardiac function was evaluated by left ventricular ejection fraction (LVEF) measurements with repeated echocardiograms, performed 2 weeks before the beginning of chemotherapy and every 6 months, until 30 months after the study entry; then yearly for at least 5 years.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Forty-seven patients were enrolled from two Italian Divisions of Medical Oncology. Final results revealed no early episodes of symptomatic CHF within the first 12 months from the enrolment. Only two cardiac events were observed: an episode of atrial flutter after the first cycle of NPL-DOX and CTX, with a quick return to normal rhythm, and a grade 3 (scored to NCI-CTCAE, version 3.0) CHF episode, 18 months later chemotherapy start. No other relevant toxicities were reported.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This adjuvant combination including NPL-DOX in elderly patients, resulted in a low rate of cardiac toxic effects. Comparative trials should be encouraged to confirm these findings.</AbstractText>
                <CopyrightInformation>Copyright © 2016 Elsevier Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Coltelli</LastName>
                    <ForeName>Luigi</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Medical Oncology, Pontedera Hospital, Azienda Toscana Nord Ovest, via Roma 151, 56025 PI, Italy. Electronic address: luigi.coltelli@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fontana</LastName>
                    <ForeName>Andrea</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Medical Oncology II, Azienda Toscana Nord Ovest, S. Chiara Hospital, via Roma 67, 56126 PI, Italy. Electronic address: andrea.fontana@aruba.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lucchesi</LastName>
                    <ForeName>Sara</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Medical Oncology, Pontedera Hospital, Azienda Toscana Nord Ovest, via Roma 151, 56025 PI, Italy. Electronic address: lucchesisara@libero.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ginocchi</LastName>
                    <ForeName>Laura</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Medical Oncology, Pontedera Hospital, Azienda Toscana Nord Ovest, via Roma 151, 56025 PI, Italy. Electronic address: lauraginocchi@hotmail.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bocci</LastName>
                    <ForeName>Guido</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical and Experimental Medicine, University of Pisa, via Roma 67, 56126 PI, Italy. Electronic address: guido.bocci@med.unipi.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Filidei</LastName>
                    <ForeName>Mario</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Medical Oncology, Pontedera Hospital, Azienda Toscana Nord Ovest, via Roma 151, 56025 PI, Italy. Electronic address: m.filidei@uslnordovest.toscana.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Scalese</LastName>
                    <ForeName>Marco</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Clinical Physiology, Italian National Research Council - CNR, via G. Moruzzi 1, 56126 PI, Italy. Electronic address: scalese@ifc.cnr.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Arrighi</LastName>
                    <ForeName>Giada</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Medical Oncology, Pontedera Hospital, Azienda Toscana Nord Ovest, via Roma 151, 56025 PI, Italy. Electronic address: giada.arrighi@uslnordovest.toscana.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Finale</LastName>
                    <ForeName>Chiara</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Medical Oncology, Pontedera Hospital, Azienda Toscana Nord Ovest, via Roma 151, 56025 PI, Italy. Electronic address: chiarafinale@libero.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Marcucci</LastName>
                    <ForeName>Lorenzo</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Medical Oncology, Pontedera Hospital, Azienda Toscana Nord Ovest, via Roma 151, 56025 PI, Italy. Electronic address: lorenzo.marcucci@uslnordovest.toscana.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Goletti</LastName>
                    <ForeName>Orlando</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>Translational Department- University of Pisa, via Roma 67, 56126 PI, Italy. Electronic address: o.goletti@med.unipi.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Salvadori</LastName>
                    <ForeName>Barbara</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Medical Oncology II, Azienda Toscana Nord Ovest, S. Chiara Hospital, via Roma 67, 56126 PI, Italy. Electronic address: b.salvadori@ao-pisa.toscana.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ferrarini</LastName>
                    <ForeName>Ilaria</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Medical Oncology II, Azienda Toscana Nord Ovest, S. Chiara Hospital, via Roma 67, 56126 PI, Italy. Electronic address: ilaria.ferrarini84@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bona</LastName>
                    <ForeName>Eleonora</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Palliative Care, Livorno Hospital, Azienda USL 6 of Livorno, via V. Alfieri 36, 57100, Livorno, LI, Italy. Electronic address: bonaeleonora@tiscali.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Falcone</LastName>
                    <ForeName>Alfredo</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Medical Oncology II, Azienda Toscana Nord Ovest, S. Chiara Hospital, via Roma 67, 56126 PI, Italy; Division of Medical Oncology, Department of Translational Research and New Technology in Medicine and Surgery, University of Pisa, via Roma 67, 56126 PI, Italy. Electronic address: alfredo.falcone@med.unipi.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Allegrini</LastName>
                    <ForeName>Giacomo</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Medical Oncology, Pontedera Hospital, Azienda Toscana Nord Ovest, via Roma 151, 56025 PI, Italy. Electronic address: g.allegrini@uslnordovest.toscana.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>11</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Breast</MedlineTA>
            <NlmUniqueID>9213011</NlmUniqueID>
            <ISSNLinking>0960-9776</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C506643">liposomal doxorubicin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>3WJQ0SDW1A</RegistryNumber>
                <NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>80168379AG</RegistryNumber>
                <NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8N3DW7272P</RegistryNumber>
                <NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>P88XT4IS4D</RegistryNumber>
                <NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003520" MajorTopicYN="N">Cyclophosphamide</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004452" MajorTopicYN="N">Echocardiography</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006321" MajorTopicYN="N">Heart</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName>
                <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
                <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011092" MajorTopicYN="N">Polyethylene Glycols</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013318" MajorTopicYN="N">Stroke Volume</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">Adjuvant chemotherapy</Keyword>
            <Keyword MajorTopicYN="Y">Breast</Keyword>
            <Keyword MajorTopicYN="Y">Cancer</Keyword>
            <Keyword MajorTopicYN="Y">Cyclophosphamide</Keyword>
            <Keyword MajorTopicYN="Y">Doxorubicin</Keyword>
            <Keyword MajorTopicYN="Y">Elderly</Keyword>
            <Keyword MajorTopicYN="Y">Liposomal</Keyword>
            <Keyword MajorTopicYN="Y">Non-pegylated</Keyword>
            <Keyword MajorTopicYN="Y">Paclitaxel</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>08</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2016</Year>
                <Month>11</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>11</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>3</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27886643</ArticleId>
            <ArticleId IdType="pii">S0960-9776(16)30236-3</ArticleId>
            <ArticleId IdType="doi">10.1016/j.breast.2016.11.006</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>